Jenburkt Pharmaceuticals Share Price Today

Counter Cyclical raises Jenburkt Pharma stake to 5.01% via open market

Counter Cyclical Investments Private Limited acquired 326 shares of Jenburkt Pharmaceuticals on October 9, 2026. The acquisition raised the portfolio manager's total holding to 220,931 shares. Shareholding increased from 4.99% to 5.01%, crossing the mandatory disclosure threshold. The purchase was made through the open market and is not linked to promoter group activity.

Jenburkt Pharma shares admitted to NSE 'Permitted to Trade' category

Shares admitted to NSE 'Permitted to Trade' category effective August 17, 2026. Company confirms it did not apply for NSE listing; primary listing remains on BSE. Admission based on NSE Circular No. NSE/CML/75748 dated August 14, 2026.

Jenburkt Pharmaceuticals accepts Vinay Bhatt resignation as Sr. VP

Jenburkt Pharmaceuticals accepts Vinay Bhatt's resignation as Sr. VP International Business. Effective date is September 18, 2026, citing personal reasons. Bhatt served the company for 21 years before exiting. Filing made under SEBI LODR Regulation 30(4). Company prioritizes business continuity during handover.

Jenburkt Pharma AGM passes resolutions with 99.99% shareholder support

Jenburkt Pharma AGM passed all resolutions with 99.99% support. Dilip H. Bhuta re-appointed as CFO for five years effective April 2027. Dividend of ₹20.70 per share (207%) declared for FY26. Promoters voted 19.16 lakh shares; public participation was low at 0.42%. No adverse qualifications in statutory or secretarial audit reports.

Jenburkt Pharmaceuticals elevates Prem Ashish Bhuta to AVP role

Prem Ashish Bhuta elevated to AVP – Strategic Initiatives effective September 4, 2026. Bhuta joins senior management after progressing from Management Associate since July 2021. He holds an MS in Integrated Marketing from New York University. Key contributions include building ZIXA Strong brand and deploying sales tech for 700+ employees. Bhuta is related to Promoter and CMD Ashish U. Bhuta.

Jenburkt Pharmaceuticals Q1FY27 net profit falls 24% to ₹5.89 crore

Jenburkt Pharmaceuticals' Q1FY27 standalone net profit fell 24.45% YoY to ₹5.89 crore, driven by increased employee benefit expenses and other costs despite flat revenue. The Board approved the results on August 6, 2026, compliant with SEBI regulations.